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Background: Until now, FISH has been the gold standard technique to identify HER2 amplification status in
ambiguous cases of breast cancer. Alternative techniques have been developed to increase the capacities of
investigating HER2 amplification status. The aims of this multicenter study in a large series of breast cancer patients
were to prospectively compare the level of performance of CISH, SISH, and qPCR alternative techniques on paraffin-
embedded core biopsies with “gold standard FISH” for evaluation of HER2 amplification status.
Methods: This study was performed on 840 cases scored by immunohistochemistry (IHC): 0=317 (38%), 1+=183
(22%), 2+=109 (13%), 3+=231 (27%). Each of the 15 French centers participating in the study analyzed 56 breast
carcinoma cases diagnosed on fixed paraffin-embedded core biopsies. HER2 amplification status was determined by
commercially available FISH used as the reference technique with determination of the HER2/CEN17 ratio or HER2
copy number status. The alternative techniques performed on the same cases were commercially available SISH or
CISH and a common qPCR method especially designed for the study including a set of 10 primer pairs: 2 for HER2
(exons 8 and 26), 5 to evaluate chromosome 17 polysomy TAOK1, UTP6, MRM1, MKS1, SSTR2 and 3 for diploidy
control TSN, LAP3 and ADAMTS16.
Results: The concordance between IHC and FISH was 96% to 95% based on the HER2/CEN17 ratio (n=766) or HER2
copy number (n=840), respectively. The concordance of the alternative techniques with FISH was excellent: 97%
and 98% for SISH (498 and 587 cases), 98% and 75% for CISH (108 and 204 cases) and 95% and 93% (699 and 773
cases) for qPCR based on the HER2/CEN17 ratio or HER2 copy number, respectively. Similarly, sensitivity ranged
from 99% to 95% for SISH, 100% to 99% for CISH and 89% to 80% for qPCR. The concordance with FISH (ratio) in
the 2+ cases was 89% for SISH, 100% for CISH and 93% for qPCR.
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Conclusion: These alternative techniques showed an excellent concordance with FISH in core biopsies allowing
their use in routine clinical practice. This newly designed qPCR on paraffin-embedded core biopsies deserves
special attention, as it is reliable, easy to perform and less expensive than ISH tests.
Keywords: HER2, FISH, SISH, CISH, qPCR, Multicenter analysisBackground
HER2 overexpression occurs in 14% to 20% of early
breast cancers. The poor prognosis initially described
for these HER2-positive cases has been corrected by the
development of a humanized monoclonal antibody,
trastuzumab (HERCEPTIN®) that significantly improves
the survival of patients with HER2-positive status, as
demonstrated by numerous clinical trials [1,2]. Immu-
nohistochemistry (IHC) using scoring tools such as the
“Hercept scale” and, more recently, the ASCO/CAP scale,
was the simplest way to identify positive cases likely to
benefit from trastuzumab [3]. However, according to this
scale, HER2 amplification of 2+ cases had to be confirmed
by Fluorescent in situ hybridization (FISH).
IHC is susceptible to interobserver variability and, as
with any assay technique, required standardization and
validation [3-10]. A very good correlation has been dem-
onstrated between HER2 protein overexpression and
HER2 gene amplification [11]. Therapeutic response to
trastuzumab was observed exclusively in patients har-
boring HER2 gene amplification [12]. Some neoadjuvant
studies suggested that the level of response was corre-
lated with the level of gene amplification [13], while
large-scale prospective adjuvant clinical trials failed to
demonstrate this correlation [14]. HER2 amplification
status can be analyzed by FISH, which is a sensitive and
specific method that identifies the number of copies of the
HER2 gene often in conjunction with the chromosome 17
centromere and is considered to be the “gold standard”.
However, FISH is not readily available, requires very spe-
cific training [15], is time-consuming requiring the use of
a fluorescent microscope and cytogenetic skills, and is also
expensive. Chromogenic in situ hybridization (CISH) [16]
and silver-enhanced in situ hybridization (SISH) [17-21]
are new bright field techniques that have been more re-
cently introduced for determination of HER2 gene status.
Quantitative real-time polymerase chain reaction (qPCR)
is such a rapid, sensitive and quantitative alternative tech-
nique [22-29], requiring small amounts of tissue and
which can be performed on paraffin-embedded samples.
Moreover, it has a high throughput capacity.
The main objective of this multicenter study, based on
large series of patients, was to prospectively compare the
performance level of the CISH, SISH and qPCR alternative
techniques on core biopsy specimens with the “goldstandard FISH” for evaluation of HER2 amplification
status. The second objective was to conduct a medico-
economic study, which is not reported in this paper. This
study was conducted by 15 hospitals homogeneously
distributed throughout France in the framework of a
project entitled "Support Program for Costly Diagnostic
and Therapeutic Innovations" supported by the French
Institute of Cancer (INCa).
Results
Population characteristics
The mean age of the patients included in the study was
58.6 years; 92% of women had non-inflammatory breast
cancer, and the mean clinical diameter of the lesion was
26.75 mm.
The study was confined to core biopsies performed
before therapy: 89% of core biopsies were microbiopsies,
including 81% of 14 G needle biopsies. The median
value of tumor cellularity was 60% (5-100). The
intraductal component represented a mean of 3.9%.
Only 12% of core biopsies had a fixation time of less
than 4 hours.
Immunohistochemistry and FISH
IHC and FISH with HER2 copy number were available
for 840 breast cancer cases: 766 cases were analyzed by
a double probe technique allowing calculation of both
HER2 copy number and HER2/CEN17 ratio. The
remaining 74 cases were analyzed by a mono-probe
technique only taking into account HER2 copy number.
A strong correlation was observed between the ASCO/
CAP score for IHC and the FISH level of amplification
(Tables 1 and 2). On FISH, 223/766 (29%) cases had a
ratio greater than 2.2 (Table 1) and 248/840 (29.5%) cases
had an HER2 copy number greater than 6 (Table 2).
Among the 3+ IHC cases, 95.2% had an HER2/CEN17
ratio greater than 2.2, and 95.2% had an HER2 copy
number greater than 6. Among the 2+IHC cases, 16.8%
had an HER2/CEN17 ratio greater than 2.2, 21.1% had
an HER2 copy number greater than 6 and 2.2% had a
borderline HER2/CEN17 ratio (1.8-2.2). In the 1+ IHC
category, 1.75% of cases had an HER2/CEN17 ratio
greater than 2.2 and 1.75% of cases had a borderline ratio.
Only 2.2% of the 1+ cases had an HER2 copy number
greater than 6. A similar correlation was obtained with the
Table 1 Distribution of the 766 cases analyzed by double probe FISH expressed as HER2/CEN17 ratio in 3 categories
with respect to the CISH, SISH and QPCR alternative techniques
Techniques Class Number of cases FISH ratio <1.8 N=534 (%) FISH ratio [1.8-2.2] N=9 (%) FISH ratio >2.2 N=223 (%)
IHC 0 287 282 (98.2) 3 (1) 2 (0.8)
1+ 172 166 (96.5) 3 (1.75) 3 (1.75)
2+ 95 77 (81) 2 (2.2) 16 (16.8)
3+ 212 9 (4.2) 1 (0.4) 202 (95.2)
SISH <1.8 331 327 (98.8) 3 (0.9) 1 (0.3)
[1.8-2.2] 11 7 (63.7) 3 (27.3) 1 (9)
>2.2 156 10 (6.4) 1 (0.6) 145 (92.9)
ND or NA 268 190 2 76
CISH <1.8 75 74 (98.7) 1 (1.3) 0
[1.8-2.2] 0 0 0 0
>2.2 33 2 (6) 0 31 (94)
ND or NA 658 458 8 192
qPCR <1.8 492 471 (95.7) 5 (1) 16 (3.3)
[1.8-2.2] 12 5 (41.7) 0 7 (58.3)
>2.2 195 12 (6.2) 3 (1.5) 180 (92.3)
ND or NA 67 46 1 20
ND: not done.
NA: not available.
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CEN17 ratio >2.2 and 0.4% of cases had an HER2 copy
number greater than 6.
As shown in Additional file 1: Table S3, results are
very similar when the HER2/CEN 17 ratio cutoff is set
at 2. In this situation, the number of patients eligible for
Trastuzumab is higher for SISH (n=6) and qPCR (n=4)
and identical for CISH.Table 2 Distribution of the 840 cases analyzed by mono or do
set at 6 HER2 copies) with respect to the CISH, SISH and QPC







ND or NA 243
CISH <6 89
>=6 115
ND or NA 636
qPCR <6 576
>=6 197
ND or NA 67
ND: not done.
NA: not available.Concordance between FISH and alternative techniques
The results of IHC, FISH and alternative techniques are
presented in Tables 1 and 2, expressed in terms of the
HER2/CEN17 ratio in 3 categories and the HER2 copy
number, respectively. Concordances and predictive values
are presented in Tables 3 and 4.
Each center was required to perform IHC, FISH, SISH
or CISH and qPCR for each case. For various reasons,uble probe FISH expressed as HER2 copy number (cutoff
R alternative techniques
Number <6 N=592 (%) FISH Copies Number >=6 N=248 (%)
316 (99.6) 1 (0.4)
179 (97.8) 4 (2.2)
86 (78.9) 23 (21.1)
11 (4.8) 220 (95.2)
409 (98) 8 (2)
4 (2.4) 166 (97.6)
179 74
88 (98.8) 1 (0.2)
49 (42.6) 66 (57.4)
455 181
531 (92.2) 45 (7.8)
12 (6) 185 (94)
49 18
Table 3 Predictive value of each alternative technique compared with FISH expressed as HER2/CEN17 ratio in 3
categories in the overall population (n=766) and in the IHC 2+ subpopulation




IHC All (N=766) 96% [94-97] 91% [86-94] 98% [97-99] 95% [91-98] 96% [94-98]
SISH All (N=498) 97% [96-99] 99% [95-100] 97% [94-98] 93% [88-96] 99% [98-100]
IHC 2+ (N=54) 89% [77-96] 80% [44-97] 91% [78-97] 67% [35-90] 95% [84-99]
CISH All (N=108) 98% [93-100] 100% [89-100] 97% [91-100] 94% [80-99] 100% [95-100]
IHC 2+ (N=18) 100% [81-100] 100% [16-100] 100% [79-100] 100% [16-100] 100% [79-100]
qPCR All (N=699) 95% [93-96] 89% [83-93] 97% [95-98] 92% [88-96] 95% [93-97]
IHC 2+ (N=86) 93% [85-97] 73% [45-92] 97% [90-100] 85% [55-98] 95% [87-98]
CI: confidence interval.
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were unable to perform all methods.
Among the 498 cases evaluable by SISH with FISH
expressed as a ratio, 156 had an HER2/CEN17 ratio
greater than 2.2 (Table 1) and a global concordance of
97% with FISH (Table 3). The Figure 1 shows the correl-
ation between FISH and CISH in terms of HER2/CEN17
ratio expressed in 3 categories. Among the 587 cases
evaluable by SISH with FISH expressed as HER2 copy
number, 170 cases had an HER2 copy number greater
than 6 (Table 2) with a global concordance of 98% with
FISH (Table 4). The Figure 2 shows the correlation
between FISH and SISH in terms of HER2/CEN17 ratio
expressed in 3 categories.
Among the 108 cases analyzed by CISH with FISH
expressed as a ratio, 33 had an HER2/CEN17 ratio greater
than 2.2 (Table 1) and a global concordance 98% with
FISH (Table 3). On the 115 of cases who had an HER2
copy number greater than 6 (Table 2) we observed only
75% concordance between the two methods (Table 4).
Of the 699 cases analyzed by qPCR with FISH
expressed as a ratio, 195 cases had an HER2/CEN17 ra-
tio greater than 2.2 (Table 1) and a global concordance
of 95% with FISH (Table 3). The Figure 3 shows the cor-
relation between FISH and qPCR in terms of HER2/
CEN17 ratio expressed in 3 categories.Table 4 Predictive value of each alternative technique compa
at 6 HER2 copies) in the overall population (n=840) and in th
Techniques Population Concordance (95%CI) Sensitivity (95%
IHC All (N=840) 95% [94-97] 89% [84-92]
SISH All (N=587) 98% [96-99] 95% [91-98]
IHC 2+ (N=60) 90% [81-96] 72% [47-90]
CISH All (N=204) 75% [69-81] 99% [92-100]
IHC 2+ (N=27) 62% [42-79] 100% [40-100]
qPCR All (N=773) 93% [91-94] 80% [75-85]
IHC 2+ (N=86) 86% [78-92] 45% [24-68]
CI: confidence interval.Among the 773 cases analyzed by qPCR with FISH
expressed as HER2 copy number, 197 had an HER2 copy
number greater than 6 (Table 2) corresponding to 93%
of global concordance with FISH (Table 4).
Predictive value of each alternative technique
The sensitivity of qPCR appeared to be slightly lower than
that of CISH and SISH. However, a higher sensitivity was
observed when FISH was expressed as the HER2/CEN17
ratio in 3 categories (Table 3) than when it was expressed
as HER2 copy number (Table 4). A very high specificity
(97%) was observed for 3 alternative techniques when
FISH was expressed as the HER2/CEN17 ratio. When
FISH was expressed as HER2 copy number, SISH and
qPCR were associated with very high specificities (99%
and 98% respectively), while the specificity of CISH was
only 64%.
When the HER2/CEN17 ratio cutoff was set at 2, the
level of predictive value is quite similar (Additional file 1:
Table S4).
Predictive value of alternative techniques in the
subpopulation of 2+ cases
A marked heterogeneity was observed between the 15
centers in terms of the proportion of amplified cases
(FISH HER2/CEN17 ratio greater than 2.2) among thered with FISH expressed as HER2 copy number (cutoff set
e IHC 2+ subpopulation




98% [97-99] 95% [92-98] 95% [93-97]
99% [98-100] 98% [94-99] 98% [96-99]
96% [87-100] 87% [60-98] 91% [81-97]
64% [56-72] 57% [48-67] 99% [94-100]
56% [35-76] 27% [8-55] 100% [77-100]
98% [96-99] 94% [90-97] 92% [90-94]
97% [91-100] 83% [52-98] 86% [77-93]
Figure 1 Correlation between FISH and CISH in terms of HER2/CEN17 ratio mentioning the three categories cutoff.
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25% in nine centers and more than 25% in the other three
centers. The results, especially the CISH results, must be
interpreted cautiously in view of the small number of 2+
cases analyzed by an alternative technique (86 for qPCR,
54 for SISH and only 18 for CISH). Indeed, CISH
appeared to have very good predictive values for 2+ cases,
but this could not be formally demonstrated due to the
small number of cases.
When FISH was expressed as a ratio in 3 categories
(Table 3), the highest concordance was observed for
CISH (100%) followed by qPCR (93%) and SISH (89%).
When FISH was expressed as copy number (Table 4),
the highest concordance was observed for SISH (90%)
followed by qPCR (86%) and CISH (62%).
Except for CISH, lower sensitivity was observed when
FISH was expressed as HER2 copy number rather than
HER2/CEN17 ratio (72% for SISH and 45% for qPCR).
When FISH was expressed as HER2/CEN17 ratio, the
highest specificity was observed for SISH and very simi-
lar results were observed for qPCR (97%) and for CISH
(91%). When FISH was expressed as HER2 copy number,
high specificities were observed for SISH and qPCR,
while CISH specificity was only 56%.
When the HER2/CEN17 ratio cutoff was set at 2, the
level of predictive value is quite similar; higher specifi-
city level was observed for qPCR (Additional file 1:
Table S4).Discussion
We have previously demonstrated the accuracy of
HER2 determination on core biopsies with respect to
surgical resection by using alternative techniques to
FISH such as CISH and SISH [17]. The present multi-
center study, performed on consecutive cases from 15
French institutions, is the largest series performed on
paraffin-embedded diagnostic core biopsies, demon-
strating correlations between IHC, FISH and additional
alternative methods i.e. CISH or SISH and qPCR. Few
analyses have been done on needle core biopsies exclu-
sively and in a so large multicenter manner. Analysis of
core biopsies represents real clinical practice for patients
receiving neoadjuvant therapy. The global concordance of
IHC with FISH in these cases was excellent and compar-
able to that reported in previous studies mainly performed
on surgical specimens [9,31-33]. Each of the 15 participat-
ing institutions had to use the alternative “in situ” tech-
nique used routinely in their respective laboratory, which
explains why only 204 cases of this series were analyzed by
CISH. Following completion of this study, CISH was
widely replaced by SISH, which is more rapid, more repro-
ducible and more easily automated [31]. However in this
study, the concordance between CISH and FISH was ex-
cellent and similar to that reported in previous studies
[34-37]. SISH gave also an excellent concordance with
FISH in this series, i.e. comparable to that previously
reported [18-21], for example Papouchado’s study based
Figure 2 Correlation between FISH and SISH in terms of HER2/CEN17 ratio mentioning the three categories cutoff.
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92.1% with a high level of reproducibility (96.6%) between
ten pathologists [18].
The correlation between FISH and qPCR was also
excellent. Despite the heterogenous variable expertise of
the various participants at the beginning of the study,
the preliminary training steps, the common protocol
and common controls and reagents resulted in an excel-
lent yield, as only seven cases were not interpretable and
only three cases had to be repeated in a second series of
slides (not shown). Molecular analysis was performed on
paraffin-embedded core biopsies in contrast with most
published studies, which were generally performed on
frozen surgical material [22-25]. Some studies were
performed on paraffin sections but were based on a small
number of cases and used the HER-2/neu Quantification
Kit™ developed by Roche for a LightCycler platform
[26-28]. This kit has now been withdrawn from the mar-
ket, as it was shown to be not optimal to detect chromo-
some 17 polysomy [29]. With a concordance of 95% with
FISH, the results of the present study are comparable to
those of previous studies [23-29]. The qPCR assay
designed for this study was performed with five probes lo-
cated on chromosome 17 (arm 17q) to distinguish betweenchromosome 17 polysomy and HER2 focal amplification.
Overall, the correlation with FISH was better in the overall
population and in the 2+ cases when the results were
expressed as the HER2/CEN17 ratio, suggesting that
this is a suitable approach. The potential disadvantage
of qPCR is that it cannot avoid dilution artefacts inherent
to DNA extraction in heterogeneous tumor specimens.
Macrodissection is now used in the routine detection of
KRAS, EGFR, BRAF… mutations and its systematic use in
this study could have further improved the performances of
qPCR in cases with low cellularity. However, the high level
of cellularity (median value of 60%) and the low percent-
age of in situ component observed in this series should
be stressed. These results on paraffin sections are very
encouraging for routine clinical practice, as, when study-
ing paraffin-embedded material, DNA material is easier
to use than RNA, which is more sensitive to fixation
conditions and degradation, resulting in a potential risk
of HER2 misclassification [38]. At last, the high through-
put capacity of qPCR and its attractive cost price are
worth noting.
We observed very similar results using a HER2/CEN17
ratio expressed in 3 categories or in 2 categories with a
cutoff set at 2, as it has been recently suggested.
Figure 3 Correlation between FISH and qPCR in terms of HER2/CEN17 ratio mentioning the three categories cutoff.
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in routine practice as a primary test or to more reli-
ably evaluate ambiguous 2+ cases, particularly in the
neoadjuvant setting. The frequency of HER2 amplifica-
tion demonstrated by FISH in 2+ cases is consistent
with the results published in the literature [31,39] with
16.8% of cases presenting an HER2/CEN17 ratio greater
than 2.2 and 21.1% of cases presented an HER2 copy num-
ber greater than 6. In general, the 2+ cases present low
levels of amplification and low copy numbers depending
on the percentage of true complete membrane staining
[40]. It has been demonstrated that this category may
present high rates of polysomy, which would explain why
a high copy number can be associated with an HER2/
CEN17 less than 2.2 [41], consequently improving the
positive predictive value with the true HER2 copy number.
An excellent concordance with FISH was observed for
both SISH and qPCR, the sensitivity was lower than in the
overall population, but nevertheless associated with a
better positive value for qPCR when FISH is expressed as
the HER/CEN17 ratio. These results suggest that the use
of several probes to estimate polysomy provides a better
correlation with FISH than when only the HER2 copynumber is used. Equivalent positive predictive values were
obtained when these two techniques were based on HER2
copy number.
Another important point is the fact that 2+ cases are
considered to be the most heterogeneous category,
explaining the discordance between core biopsies and
surgical specimens [42] and the technique cannot be
repeated on surgical specimens in the neoadjuvant set-
ting. These discrepancies are observed more frequently
around the cut-off used to define positivity [40].
The marked variation between centers in terms of the
level of amplification in 2+ cases suggests that the IHC
technique must be more closely standardized for these
cases. According to the guidelines, 2+ amplified cases
must be included in external controls for IHC [6,7,35],
but these cases are rare and present amplification in less
than 25% of cases, for example 14% in the Nottingham
series [42]. The 2+ cases correspond to the cases with
the most marked genetic heterogeneity [43] with a lower
level of amplification compared to 3+ cases [44]. This
amplification is related to the percentage of positive
membrane staining cells [42]. Under these conditions,
needle core biopsies are the least appropriate specimens
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situations therefore required repeated analysis or the
use of alternative techniques.
Medico-economic aspects must also be taken into ac-
count in the choice of method. The medico-economic
study is ongoing in the same patient series, but the re-
sults are not reported here.
Conclusions
This multicenter study shows that SISH, CISH and
qPCR alternative techniques to evaluate HER2 amplifi-
cation status are easy to use and provide encouraging
results. In ambiguous cases scored 2+ by IHC, the
heterogeneity, the small proportion of amplified cases,
and the lower HER2 copy number must be taken into
account in the neoadjuvant setting to assess HER2
status on core biopsies. In this case, the use of various
alternative techniques such as SISH and qPCR could be
a reliable approach.
The qPCR protocol used in the 15 participating insti-
tutions was found to be an acceptable alternative to




This study is a non-interventional study and no written
consent was needed. In agreement with the French
legislation, the protocol was approved by the Comité
Consultatif sur le Traitement de l’Information en
matière de Recherche dans le domaine de la Santé
(CCTIRS) and declared to the Commission Nationale
de l’Informatique et des Libertés (CNIL).
The required number of patients was estimated
according to the expected FISH positivity of each IHC
level according to ASCO/CAP 2007 [3]: 840 cases were
necessary: 0=317 (38%), 1+= 183 (22%), 2+= 109 (13%),
3+ =231 (27%). Each of the 15 centers complied with
this proportion by recruiting a mean of 56 cases.
Tumor cell percentage and presence of an in situ com-
ponent were assessed on Hematein/Eosin stained
sections.
A representative block of fixed paraffin-embedded
tumor tissue from each patient was selected and used to
prepare sections for IHC and FISH/SISH/CISH. Four
additional 10-μm sections were taken from the same
block for DNA extraction and qPCR.
a) IHC and in situ hybridization
All 15 centers participate in the French national annual
quality control (AFAQAP) and are members of the
GEFPICS group [4,9]. According to French guidelines,
the choice of method (IHC vs ISH, brand of antibodies
or ISH kits) is left to the pathologist’s discretion. The listof the antibodies used by the participants is given in
Additional file 1: Table S1. As different fixatives are used
in routine practice, a training step was conducted before
initiation of this study using two types of tissue micro-
arrays (TMA) representative of the fixative used in each
center. A 0.6 mm diameter needle was used for the
TMA. The first TMA was performed with alcohol for-
malin (AF) used by 41% of the participants, the second
TMA was performed with formalin (F) used by the
remaining 59% of participants. Each TMA included 13
cases 6/3+, 2/2+ 3/1+ and 2/0 and 3 control cell lines
with various HER2 amplification levels (T47D, MCF7,
BT474). The amplification level of each case was evalu-
ated by FISH by two of the authors (JJ/FPL).
Each participant was required to validate IHC and
CISH or SISH and FISH in situ techniques on the TMA
depending on the fixative used in the center (AF or F).
The good concordance obtained (92%) allowed initiation
of the study. The cases included in these TMA were also
used for qPCR training.
The 2007 ASCO/CAP [3,30] guidelines were used to
define IHC categories: negative = no membrane staining,
1+ = faint or barely perceptible membrane staining, 2+ =
10-30% of strong complete membrane staining or >10%
tumor cells with moderate complete membrane staining,
3+ = more than 30% strong complete membrane staining.
A minimum of 20 tumor nuclei are required for in situ
hybridization on core biopsy. FISH was performed with
a dual probe kit (HER2 and CEN17) HER2 FISH
pharmDx™ (Dako France SAS, Trappes, France) or Vysis
Path Vysion (Abbott France SAS, Rungis, France). A
mono-probe kit INFORM (Ventana Medical Systems
SA, Illkirch, France) was used in one center. SISH was
performed in 10 centers using the Ventana Kit on
Benchmark XT(Roche Diagnostic, Meylan, France)
(www.ventana.com). CISH was performed in 5 centers
according to the DAKO or Cytovision kits (Leica/
Cytovision, Nanterre, France). The following cut-offs were
used according to the 2007 ASCO/CAP [3,30] guidelines:
amplified (R >2.2) borderline amplification (1.8-2.2) and
non amplified (<1.8). A second analysis was performed
with the cutoff set at 2: amplified (R>=2) and non ampli-
fied (R<2).
b) qPCR
qPCR was coordinated by two of the authors (FS, IB) at
the Institut Curie - Hôpital René Huguenin (IC-HRH).
All 15 participants used the same DNA extraction pro-
cedure (QIAamp kit, Qiagen). The qPCR method was
performed in 14 centers; samples from one center were
blindly analyzed in the coordinator’s lab without know-
ledge of the IHC or FISH status. One centre participated
to the preliminary steps of the study but did not perform
the prospective study.
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levels of expertise in PCR assays. Three rounds of tests were
organized before initiating the prospective study in order to
test and standardize practices and to define the most appro-
priate primer pairs for evaluation of HER2 amplification,
chromosome 17 polysomy and diploidy controls. The refer-
ence genes, located on the same chromosome as HER2,
provide a control for DNA quality and loading and are also
used as an internal control gene to evaluate chromosome
17 polysomy. The choice of the probes used to detect
polysomy was focused on the 17q arm.
A total of 22 primer pairs were tested in three prelim-
inary tests, 7 for HER2, 8 for evaluation of chromosome
17 polysomy and 7 for diploidy control. Primer pairs
were chosen on the basis of CGH array studies
performed at the IC/HRH, published data and previous
experience of HER2 amplification on frozen breast tu-
mors [22]. The initial tool was modified during the
course of the 3 preliminary tests. The following material
was used to test the evolving tool: three consecutive
series of 15 breast cancer tumors provided by the partic-
ipants (secondarily anonymized and redistributed by the
coordinator) with known HER2 status; appropriate
controls (normal lymph nodes, cell lines) and cases with
various DNA qualities to test the robustness of the assay.
The coordinators proposed a final common protocol
to the participants for the prospective study, including
10 sets of primer pairs: 2 for HER2 (exons 8 and 26), 5
for chromosome 17 polysomy detection: TAOK1 at
17q11.2 (sub-centromeric region), UTP6 at 17q11.2
(sub-centromic region), MRM1 at 17q12, MKS1 at
17q22 and SSTR2 at 17q24, and 3 for diploidy control:
TSN at 2q14, LAP3 at 4p15 and ADAMTS16 at 5p15
(Additional file 1: Table S2).
Participants received detailed instructions on the tech-
nique and vials containing the oligonucleotides for the
10 genes and for the prospective cases to be tested, to-
gether with DNA extracted from normal lymph nodes
and SKBR-3 breast cancer cell lines, as controls for non-
amplified and amplified HER-2 gene copy, respectively.
PCR analyses were performed in duplicate in a 10 μL re-
action volume. A quantity of 200 ng DNA was necessary
for each patient for duplicate analysis of the ten genes
(10 ng/PCR reaction). Each participant used his/her own
quantitative PCR platform. Considering the threshold of
each device, most participants used Applied Biosystems
material with the same threshold set at 0.20 for the
Appled 7900 for example. For the other devices, threshold
was adapted during the preliminary steps of the study.
Participants also received Excel sheets with pre-calculated
areas from individual Ct values obtained for each gene. In
order to be comparable with FISH and SISH/CISH, qPCR
data were expressed as the median copy number of the 5
genes used for “chromosome 17 control” and assessmentof polysomy, and the median HER2 copy number. Finally,
these two numbers were used to calculate the HER2/
CEN17 ratio. Cycle threshold (Ct) values above 35 were
excluded. Cut-offs used for HER2 amplification status by
qPCR were similar to those used in in situ methods.
A database was created with the following parameters
provided by the participants:
Hematein-Eosin staining: histological type, percentage
of tumor cellularity, proportion of in situ component,
grade, core size, fixative, fixation time.
Immunohistochemistry: antibody and dilution, type of
pre-treatment, ASCO/CAP 2007 score with the percent-
age of positive cells and intensity [3].
FISH: 1) name of the kit used; 2) number of nuclei ana-
lyzed; 3) absolute and mean HER2 copy number; 4) abso-
lute and mean Chromosome 17 number; 5) HER2/CEN17
ratio and final results with the cut-off values according to
ASCO/CAP 2007 guidelines:; 5) the number of times the
technique was repeated, when applicable.
CISH and SISH were analyzed according to the same
plan.
qPCR: 1) Quality of the DNA 260/280 absorbance ratio
(evaluated by Nanodrop™); 2) HER2 copy number; 3) refer-
ence gene copy number; 4) final ratio for HER2 status
using the same cut-off values as for FISH; 5) the number
of times the technique was repeated, when applicable.
Statistical analysis
The sample size was calculated to ensure a lower
boundary of the 95% confidence interval of sensitivity
and specificity to be upper than 80%. This calculation
was based on the CI95’s formula for a proportion.
Data were summarized by frequency and percentage
for categorical variables and the median and range were
computed for continuous variables.
The predictive capabilities of each experimental tech-
nique were described by concordance percentage, sensi-
tivity, specificity, and positive and negative predictive
values, considering FISH as the reference technique.
A sample size of 850 cases was required to demonstrate
sensitivity and specificity greater than 80%, on the basis of
the lower boundary of the 95% confidence interval of a
proportion. A total of 840 evaluable cases were finally
included.
Statistical analysis was performed using R.2.15.0
software.
Additional file
Additional file 1: Table S1. List of the antibodies used for
immunohistochemistry according to the french and AFAQAP guidelines.
Table S2. List of primers used for the qPCR method. Table S3.
Distribution of the 766 cases analyzed by double probe FISH expressed
as HER2/CEN17 ratio with a cutoff set at 2 with respect to the CISH, SISH,
Jacquemier et al. BMC Cancer 2013, 13:351 Page 10 of 11
http://www.biomedcentral.com/1471-2407/13/351and QPCR alternative techniques. Table S4. Predictive value of each
alternative technique compared with FISH expressed as HER2/CEN17 ratio
with a cutoff set at 2 in the overall population (n=766) and in the IHC 2+
subpopulation.
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